These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29943711)

  • 1. Activity of Ceftolozane-Tazobactam against
    Slack A; Parsonson F; Cronin K; Engler C; Norton R
    Am J Trop Med Hyg; 2018 Aug; 99(2):281-282. PubMed ID: 29943711
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Chan E; Martelli P; Hui SW; Teng JLL; Lau SKP; Woo PCY
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29483111
    [No Abstract]   [Full Text] [Related]  

  • 3. Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital.
    López-Calleja AI; Morilla Morales E; Nuñez Medina R; Fernández Esgueva M; Sahagún Pareja J; García-Lechuz Moya JM; Ferrer Cerón I; Viñuelas Bayon J; Rezusta López A
    Rev Esp Quimioter; 2019 Feb; 32(1):68-72. PubMed ID: 30547503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibility pattern of clinical isolates of Burkholderia pseudomallei in Bangladesh.
    Dutta S; Haq S; Hasan MR; Haq JA
    BMC Res Notes; 2017 Jul; 10(1):299. PubMed ID: 28728591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Flamm RK; Castanheira M
    J Glob Antimicrob Resist; 2017 Sep; 10():186-194. PubMed ID: 28735046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patients to ceftolozane/tazobactam and ceftazidime/avibactam.
    Sribenjalux W; Wonglakorn L; Meesing A
    J Glob Antimicrob Resist; 2022 Mar; 28():8-11. PubMed ID: 34922057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers.
    Giani T; Arena F; Pollini S; Di Pilato V; D'Andrea MM; Henrici De Angelis L; Bassetti M; Rossolini GM;
    J Antimicrob Chemother; 2018 Mar; 73(3):664-671. PubMed ID: 29216350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
    Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
    Farrell DJ; Sader HS; Flamm RK; Jones RN
    Int J Antimicrob Agents; 2014 Jun; 43(6):533-9. PubMed ID: 24856078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antibiotics of choice for the treatment of melioidosis in Indian set up.
    Shaw T; Tellapragada C; Eshwara VK; Bhat HV; Mukhopadhyay C
    Indian J Med Microbiol; 2016; 34(3):353-4. PubMed ID: 27514960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.
    Shields RK; Clancy CJ; Pasculle AW; Press EG; Haidar G; Hao B; Chen L; Kreiswirth BN; Nguyen MH
    J Clin Microbiol; 2018 Feb; 56(2):. PubMed ID: 29167294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
    Pfaller MA; Bassetti M; Duncan LR; Castanheira M
    J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
    Henderson A; Tan E; McCarthy KL; Paterson DL
    Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
    Tato M; García-Castillo M; Bofarull AM; Cantón R;
    Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Schmidt-Malan SM; Mishra AJ; Mushtaq A; Brinkman CL; Patel R
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29760145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.
    Melchers MJ; van Mil AC; Mouton JW
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4521-5. PubMed ID: 25987635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16.
    Walkty A; Adam H; Baxter M; Lagacé-Wiens P; Karlowsky JA; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2018 Mar; 73(3):703-708. PubMed ID: 29244121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year surveillance for Burkholderia pseudomallei in Thailand from 2000 to 2004: prevalence and antimicrobial susceptibility.
    Paveenkittiporn W; Apisarnthanarak A; Dejsirilert S; Trakulsomboon S; Thongmali O; Sawanpanyalert P; Aswapokee N
    J Med Assoc Thai; 2009 Aug; 92 Suppl 4():S46-52. PubMed ID: 21298845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.